Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$60.89 0.48 (0.78%) as of 4:30 Thu 4/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 139,010,000 as of 9/30
Market Cap: 8.46(B)
Last Volume: 1,838,811 Avg Vol: 1,245,512
52 Week Range: $54.72 - $83.28
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,297
Total Buy Value $0 $0 $0 $31,835
Total People Bought 0 0 0 3
Total Buy Transactions 0 0 0 3
Total Shares Sold 63,370 193,811 522,160 1,820,663
Total Sell Value $4,925,327 $13,875,589 $36,202,567 $95,867,363
Total People Sold 5 8 11 16
Total Sell Transactions 5 20 62 168
End Date 2014-01-16 2013-10-15 2013-04-16 2012-04-16

   
Records found: 1204
  Page 1 of 49  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-03-28 4 OE $12.99 $25,980 I/I 2,000 48,740     -
   Slamon Dennis Director   –       •      –    2014-03-19 3 IO $0.00 $0 D/D 0 700 -24%     
   Slamon Dennis Director   –       •      –    2014-03-19 4 A $0.00 $0 D/D 4,000 4,700     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-03-06 4 OE $21.51 $473,165 D/D 17,370 42,750     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-03-06 4 AS $78.63 $1,365,831 D/D (17,370) 25,380 -26%     
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-03-03 4 OE $39.06 $312,480 D/D 8,000 72,273     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-03-03 4 AS $80.32 $642,530 D/D (8,000) 64,273 -28%     
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-20 4 OE $21.51 $430,200 D/D 20,000 80,656     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-20 4 AS $80.00 $1,600,000 D/D (20,000) 60,656 -29%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-20 4 AS $80.00 $640,000 I/I (8,000) 46,740 -29%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-14 4 A $0.00 $0 D/D 78,750 194,520     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-14 4 A $0.00 $0 D/D 26,250 86,600     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-02-14 4 A $0.00 $0 D/D 10,500 60,656     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-02-14 4 A $0.00 $0 D/D 26,250 64,273     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-02-14 4 A $0.00 $0 D/D 10,500 25,380     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-14 4 A $0.00 $0 D/D 31,500 73,850     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-02-06 4 OE $12.99 $51,960 I/I 4,000 54,740     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-04 4 GD $0.00 $0 D/D 2,675 60,350     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-02-04 4 GA $0.00 $0 I/I 2,675 13,722     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-03 4 OE $21.51 $215,100 D/D 10,000 52,350     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-02-03 4 AS $67.70 $676,966 D/D (10,000) 42,350 -15%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-10 4 OE $12.99 $64,950 I/I 5,000 55,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-10 4 AS $70.00 $350,000 I/I (5,000) 50,740 -18%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-06 4 OE $12.99 $129,900 I/I 10,000 60,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-06 4 AS $67.40 $674,096 I/I (10,000) 50,740 -15%     

  1204 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 49
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed